James Yates

James Yates

GlaxoSmithKline - Needham / United Kingdom
Medical and Health Sciences / Pharmacology
AD Scientific Index ID: 4370665
-
person_outline James Yates's MOST POPULAR ARTICLES
1-) Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activityP Ballard, JWT Yates, Z Yang, DW Kim, JCH Yang, M Cantarini, K Pickup, ...Clinical Cancer Research 22 (20), 5130-5140, 20165862016
2-) Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic backgroundBR Davies, H Greenwood, P Dudley, C Crafter, DH Yu, J Zhang, J Li, ...Molecular cancer therapeutics 11 (4), 873-887, 20123742012
3-) Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agentKM Foote, JWM Nissink, T McGuire, P Turner, S Guichard, JWT Yates, ...Journal of medicinal chemistry 61 (22), 9889-9907, 20182102018
4-) PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based …P Poulin, RDO Jones, HM Jones, CR Gibson, M Rowland, JY Chien, ...Journal of pharmaceutical sciences 100 (10), 4127-4157, 20112222011
5-) PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearanceBJ Ring, JY Chien, KK Adkison, HM Jones, M Rowland, R Do Jones, ...Journal of pharmaceutical sciences 100 (10), 4090-4110, 20112102011